• Health and wellness supplement producer HempFusion Wellness, Inc. is aggressively expanding its reach in retail outlets across the United States and internationally to cement its leadership position in the CBD industry and prepare it for further growth
• The company recently announced an agreement that will grant it 100 percent interest in successful CBD pioneer Sagely Naturals, which has built its brand on women-centric products
• Sagely Naturals is the third-most successful CBD brand and the most successful CBD topicals brand, with 23 percent market share in the drug channel and 13.8 percent market share in the multiple outlet channel
• The M&A agreement will grant Sagely Naturals access to international markets through HempFusion’s channels, while HempFusion will make a huge leap in domestic outlets through Sagely Naturals’ channels

An M&A agreement between health supplement innovator innovator HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) and women-centric CBD topicals powerhouse Sagely Enterprises, Inc. (“Sagely Naturals”) is expected to exponentially expand both brands’ market reach in domestic and international outlets. The merger and acquisition agreement, announced May 25, will grant HempFusion immediate access to an additional 14,000-plus stores where Sagely Naturals are sold, while Sagely Naturals will receive inclusion on HempFusion’s Novel Foods Application Dossier with the United Kingdom’s Regulatory Food Safety Agency for future European expansion. “Upon closing, the acquisition of Sagely Naturals immediately adds significant value to shareholders,” HempFusion co-founder and CEO Jason Mitchell stated (https://ibn.fm/YbBA6). “By more than tripling our 2020 revenue (when combined with the closing of Apothecanna), expanding to over 15,000 stores, expanding our distribution strategy to six channels, combining some of the top executive talent in the industry, and bringing together over 75 incredible and best-selling SKUs, HempFusion is in its strongest position to date.” The Apothecanna purchase agreement, announced May 17, will grant HempFusion access to the CBD brand’s distribution channel through 1,800 stores nationwide that include CVS and 7th Sense outlets (https://ibn.fm/7COnj). Sagely Naturals co-founders and Co-CEOs Kerrigan Behrens and Kaley Nichol also praised HempFusion’s focus on compliance with regulatory standards for hemp-derived products worldwide, with a nod to HempFusion’s distribution channels in mainland China, Hong Kong, Macau, Taiwan, Mexico, South Korea and the United Arab Emirates, as well as expectations of entering India, Ireland and the UK. “HempFusion approaches the industry the right way and possesses the resources required to help us significantly scale our business, increase our market share, and expand beyond our stronghold in the United States to international jurisdictions,” Behrens stated in the M&A announcement. Under the agreement, Behrens and Nichol will remain as co-CEOs of Sagely Naturals once the company becomes a subsidiary of HempFusion, maintaining the direction of their best-in-class marketing experience, proven innovation and strong consumer relationships that include A-list celebrities such as Cameron Diaz, Zoe Saldana and Molly Sims, who participate both as consumers and investors. According to the news release, Sagely Naturals’ five SKUs have helped it maintain a position as the third-most successful CBD brand and leading CBD topicals brand, with 23 percent market share in the drug channel and 13.8 percent market share in the multiple outlet channel (“MULO”) and consistent growth even during the adverse conditions induced by the COVID pandemic during the past year. Its distribution outlets include key retailers such as CVS, Rite Aid, Albertsons, Sprouts and Nordstrom, as well as independent grocers and the company’s website. HempFusion’s branded products include broad-spectrum CBD oil tinctures, capsules and skin care focused on meeting consumer needs for sleep, stress, energy, and skin support. HempFusion also offers a line of over-the-counter topicals designed to target pain, eczema, acne and wound care. Its Probulin Probiotics, LLC, subsidiary produces probiotic products that target total gut health support and skin care, with some of the probiotic formulas targeting women’s and children’s needs, specifically. For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

• UUUU is focused on building fully integrated, rare earth supply capabilities
• Carester is recognized as leading authority, global consultants on rare earth supply chains
• Energy Fuels committed to restoring critical U.S. domestic rare earth capabilities

In its ongoing commitment to developing its rare earth element (“REE”) business, Energy Fuels (NYSE American: UUUU) (TSX: EFR) is working with Carester SAS, a leading global expert on rare earth separation (https://ibn.fm/lb61d). UUUU is working with Carester to conduct a scoping study for the development of a solvent extraction REE separation circuit at Energy Fuels’ White Mesa Mill in Utah. “Energy Fuels is absolutely focused on building fully integrated rare earth supply capabilities at our White Mesa Mill in the coming years, and we are pleased to have Carester on the team to support our efforts,” said Energy Fuels president and CEO Mark S. Chalmers, President and CEO of Energy Fuels. “Since we began evaluating the potential to produce rare earth products in late 2019, Energy Fuels has partnered with only the best global experts at every opportunity, and the agreement with Carester is just another example of how our company is advancing our strategy on the complete REE production sequence.” Last year Energy Fuels announced its intent to explore the potential of producing separated REE oxides, REE metals, REE alloys and other value-added REE products at its White Mesa Mill with the objective of creating a fully integrated U.S. REE supply chain in the coming years. Partnering with Carester represents a key component of that development. Energy Fuels and Carester will be evaluating the next steps as the company moves forward with its planned development of REE separation capabilities at the White Mesa Mill. Energy Fuels anticipates using existing equipment and infrastructure as much as possible as it works to create a continuous, integrated and optimized rare earth production sequence. Part of the study calls for Carester to evaluate the mill’s current monazite leaching process; the Carester team will also prepare an REE separation flow sheet, calculate capital and operating expense estimates, analyze where new technologies need to be incorporated and even recommend equipment vendors. Energy Fuels opted to partner with France-based Carester because its team is recognized as a leading authority and global consultants on rare earth supply chains, offering invaluable insight and expertise in designing, constructing, operating and optimizing REE production facilities globally. “Rare earth extraction, separation and purification can be complex. We believe that our extensive in-house processing experience, combined with Carester’s expertise, places the company in an excellent position to successfully and cost effectively help to restore critical domestic rare earth capabilities in the USA at the White Mesa Mill,” Chalmers said. “As more clean energy and advanced technologies are deployed, more rare earth products will be required. However, technologies are only clean if every step in the supply chain from the mine to the final consumer product is clean,” continued Chalmers. “An electric vehicle is not green if the raw materials that go into the vehicle are not responsibly produced. The U.S. has the highest standards for safety, efficiency and environmental responsibility in the world when it comes to mining, processing, refining and manufacturing. Energy Fuels is working towards establishing a clean and green U.S. option for manufacturers who demand the highest standards in their rare earth raw materials.” For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• PlantX offers consumers the opportunity to extend the benefits of a plant-based diet to their pets; offers a broad range of plant-based dog and cat food
• Plant-based dog and cat food may provide a multitude of health benefits for pets, including easing chronic symptoms such as allergies, digestive problems, joint pain, and more
• PlantX remains committed to expanding its product offering in alignment with company’s values involving health consciousness, environmental awareness, and general wellbeing

A plant-based diet brings health benefits not only to humans but to pets too. In pursuit of making plant-based living possible for consumers and their pets alike, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), has included a broad range of products targeted at human’s furry friends. From dry food and treats, a number of products are available within the plan-based pet supplies category. It spans over dog and cat food and treats, and involves premier brands such as V-Dog, Cookie Pal, Ami, Benevo, and Evolution Diet (https://ibn.fm/WQ2kh). People choose a plant-based lifestyle for a number of reasons. Although motives that cause a person to follow this kind of lifestyle can be nuanced, many of them who are pet owners wish to feed their pets in alignment with the values that encompass kindness, environmental awareness, and general wellbeing. PlantX is committed to bringing a well-balanced diet to consumers who want to help their pets living a longer and more active life while also ensuring that their lifestyles cause less animal suffering and have a far less negative impact on the environment compared to one which includes animal products. A nutritionally complete vegan diet can bring significant health benefits for pets, making it a good fit for dogs of all shapes, sizes, and ages. A change in diet will often be needed for pets that suffer from chronic symptoms like itchy skin, digestive problems, joint pain, or eye discharge. Many health problems could be eased with plant-based nutrition. Allergies may cause skin problems, digestive issues, eye discharge, yeast infections, and fur loss in dogs. A little-known fact is that grains are an uncommon cause of pets’ food allergies – most of them are allergic to animal proteins found in chicken, beef, dairy, and egg. Plant-based formulas are gentle on digestion and often free of allergens, and can provide pets with some relief from those chronic, uncomfortable symptoms (https://ibn.fm/wJwQx). A plant-based diet is also considered by many to be natural anti-inflammatory food that helps relieve joint pain and arthritis in pets, improving their mobility, and leading to stronger muscles and more endurance. With this kind of diet, dogs can regain puppy-like energy as their bodies are fueled with wholesome food containing readily available nutrition. Made with lean and easily digestible ingredients, a plant-based diet can also help dogs maintain weight and live longer, more active lives. This is especially important, as pet obesity is becoming a growing problem and the number one health threat they face. More and more pets are having issues with weight — it is estimated that a staggering 59.5% of cats and 55.8% of dogs are classified as overweight or obese (https://ibn.fm/VjrfG). Obesity reduces pets’ lives and makes them more prone to various diseases. PlantX is committed to offering consumers the opportunity to reverse these grim statistics involving their pets. It recognizes that not only people can benefit from a nutritious, plant-based diet — and not only a human diet can impact the health of our planet. It is estimated that cats’ and dogs’ food is responsible for 64 million tons of greenhouse gases released into the atmosphere every year — the equivalent of driving more than 13 million cars (https://ibn.fm/CY6xd). The Company is poised to provide consumers with a chance to align their pet’s wholesome nutrition with their own beliefs centered around ethical values that support both environmental benefits and exclude exploitation of and cruelty to animals. With a broad range of plant-based food and treats for dogs and cats, PlantX allows consumers to feed their companion animals nutritious food in a way that is protective of animal welfare and can contribute to the planet’s health. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. To visit the company’s YouTube channel, click here. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• XPhyto’s distribution, storage, and logistics partner, Max Pharma GmbH, began the sale and delivery of its rapid test kits (Covid-ID Labs) in Germany on May 25
• Max Pharma will sell Covid-ID Labs at volume-dependent pricing comparable to other COVID-19 PCR test products on the market
• The announcement comes as Germany reopens, meaning XPhyto is likely to benefit from a raft of regulatory requirements instituted by the government, which could potentially increase demand
• The Covid-ID Labs is both fast and accurate, factors that could make it the go-to product, given the inaccuracies and low sensitivity of many rapid antigen tests

As Germany reopens thanks to a drop in new COVID-19 infections, it has adopted a strategy that mandates anyone and everyone to prove they have been tested for the virus, have recently recovered from the disease, or have been fully vaccinated before entering any public space, including shops, outdoor dining areas, and, in some cases, indoor hospitality facilities (https://ibn.fm/IOo17). Earlier in March, the government made testing accessible to all at no cost, qualifying every resident to at least one free COVID-19 test per week, a policy whose implementation has continued since. As part of the arrangement, the government would reimburse companies for each test conducted (https://ibn.fm/W30qW). These regulatory requirements, plus the government’s efforts, bode well for the prospects of XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) in Germany. Recently, XPhyto, a life sciences technology accelerator, announced that Max Pharma GmbH, its distribution, storage, and logistics partner, began selling and delivering its 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) in Germany on May 25, at volume-dependent pricing comparable to other COVID-19 PCR test products on the market (https://ibn.fm/9qWGp). According to Wolfgang Probst, CEO and director of XPhyto, the company’s target customers are medical clinics, pharmacies, cruise lines, airports, and any industrial or education facility that requires rapid, definitive results. XPhyto has secured the initial German manufacturing capacity, with additional manufacturing capacity available, if need be. The commencement of the sale is a culmination of events, mainly in Germany, that fulfill XPhyto’s commitment to developing effective, accessible rapid diagnostics for early detection and the potential for better treatment outcomes and improved disease management. Its first product in the market, Covid-ID Lab is based on the reverse transcriptase-polymerase chain reaction (“RT-PCR”) method. The RT-PCR process, with occurs without prior RNA extraction, takes 20 minutes, after which the SARS-CoV-2 (COVID-19) virus is detected on a test chip, and the results can be read visually within 5 minutes. Covid-ID Lab combines the accuracy of a PCR test, the gold standard for diagnosis, with the speed of an antigen test, thereby filling the existing market gap between centralized, automated PCR systems and disposable antigen tests. It achieves this despite requiring less laboratory equipment and expertise. Notably, the high accuracy may well make XPhyto’s rapid test kit the go-to product on the market, increasing its demand, especially in light of recent revelations captured in a recent analysis by Cochrane International. The researchers, who evaluated 64 studies that compared the results of two types of rapid tests – antigen and molecular tests – with those of PCR tests conducted in the laboratory, noted that antigen tests fail to detect some infected people, given that their accuracy and sensitivity range is between 34% and 88% compared to PCR, depending on the manufacturer (https://ibn.fm/6fprg). The potential surge in demand owing to Covid-ID Lab’s higher accuracy, coupled with the mandatory testing requirements in Germany, points to the likelihood that XPhyto may soon require the additional available manufacturing capacity. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• HENC acquired majority stake in BlackBox Systems and Technologies LLC late last year
• Aeroponics is a method of growing plants in an environment with no soil
• HENC’s exclusive aeroponics technology provides optimal conditions to enhance photosynthesis, cultivation of large flowering plants

A strategic acquisition by Hero Technologies (OTC: HENC) last year has made the company a clear contender in the cannabis aeroponics cultivation space. In November 2020, HENC executed an acquisition and operating agreement resulting in the company acquiring a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that uses proprietary technology (https://ibn.fm/mSfC4). Aeroponics, or a method of growing plants in an environment with no soil, has been around since early in the 20^th century, when an article titled “On Air Plant Cultures” was published in the Experienced Agronomy journal (https://ibn.fm/qI2SD). In the article, author V.M. Artsikhovski explained his method of physiological studies of root systems, which he achieved by spraying various substances in the surrounding air. Artsikhovski designed the first aeroponics and showed its ability for plant cultivation. Since then, the method has been primarily used by scientists who wanted to be able to closely examine roots without the hindrance of dirt. However, by early in this century, aeroponics was being used in agriculture around the world as plants were suspended in a closed or semi-closed environment, with their roots sprayed with an atomized, nutrient-rich water solution. Benefits of the approach are numerous, including taking up less space than outdoor grow facilities, allowing growers to reduce the density of pesticides in their operations and providing a high degree of control (https://ibn.fm/E0ZXu). In addition, aeroponic systems are highly efficient, offering higher survival rates and a faster grow cycle than soil-based grow facilities. HENC’s exclusive aeroponics technology, called BlackBox XL Systems and Grow module, provides optimal conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased efficiencies. The BlackBox system features environmental growth chambers for the cultivation of large flowering plants. The company sees the aeroponics space combined with its proprietary technology as a significant opportunity with impressive potential. The company noted that it expects the operation to “produce approximately 6,240 lbs. of cannabis annually, which would generate approximately $21.84 million in revenue if sold at the wholesale price of $3,500 per lb or $43,680,000 if the cannabis produced is sold at retail for $7,000 per lb,” the press release noting the Blackbox acquisition stated. “We expect the BlackBox operation will yield up to 1,560 plants in a 25,000-square-foot facility.” Hero Technologies Inc. is a cannabis company working toward a vertically integrated business model. The company’s strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• Ehave announced it will utilize BRSF’s tech in an upcoming ketamine clinical study
• BRSF’s tech will make it possible to correlate biomarkers for the identification of chronic pain, depression, PTSD, bipolar disorder, and more.
• The data from this clinical trial has the potential to provide longitudinal insights that can link brain analysis and psychedelics

Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is on a mission to modernize brain diagnostics with cutting-edge tech that bridges the widening gap in access to quality care. The company’s technology will be part of a ketamine clinical study conducted by Ehave, Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. To read Ehave’s full announcement regarding the Ketamine Clinical Trial, go to https://ibn.fm/VMu6o. Ehave is a leading provider of digital therapeutics for the psychedelic and mental health sectors. The company’s primary goal is to improve standard care with digital therapeutics to prevent or treat brain disorders or diseases. By partnering with BRSF, they will leverage both data and AI to correlate biomarkers to identify chronic pain, depression, PTSD, bipolar disorder, general anxiety, ADHD, and schizophrenia. The trial will begin the second half of 2021 and will need to enroll 35 patients. Ehave will be studying the effect of ketamine as a treatment for major depression while assessing the candidate therapy’s safety and tolerability. Mental health disorders, in the wake of Covid-19, are on the rise. Depression alone affects over 264 million worldwide, and drug overdoses have risen 42% since the pandemic began. “Ehave’s goal,” stated Alfred Farrington II, CIO of Ehave, “is to help practitioners make more informed decisions about mental health care. We believe the data from this clinical trial will provide longitudinal insights that can link brain analysis and psychedelics.” Using BRSF’s technology, Ehave will be able to brain map the volunteer patients and show changes in the neuroplasticity of the brain areas impacted by the treatment. This study has the potential to create new forms of treatment for chronic mental health disorders. BRSF’s neurological devices, NeuroCap(TM) and NeuroEEG(TM) are portable, clinical-grade, cost-efficient, easy-to-use, and allow for long-term monitoring. In addition to these benefits, BRSF’s technology is ideal for clinical studies because of the company’s AI-assisted diagnostic analysis that increases the efficiency, consistency and accuracy of the data collected. Ehave is the newest to join the quickly expanding list of clinical studies that have taken advantage of BRSF’s next-generation technological solutions for the neurology market. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Dr. Edward “Ned” Swanson has joined Healthtech as CEO, bringing decades of scientific, clinical, industry and capital markets experience, including founding NASDAQ-listed company, to HLTT
• Healthtech in recent months has committed to a portfolio strategy, where it will bring diverse group of healthtech companies forward
• Company acquired precision oncology company Varian Biopharmaceuticals Inc. (“VarianBio”) in May, adding it to their family of companies that already included MediScan and RevHeart
• The biotech portfolio model is hot, with over $5.5 billion in capital raised in the last six years

Historically, biotech companies built value nearly exclusively with a straightforward approach centered on a specific market segment. While that still may be true in many cases, the landscape has shifted with more companies employing a portfolio model that leverages a broader skillset of a management team to oversee a diverse group of businesses. As it advances a groundbreaking imaging technology, HealthTech Solutions (OTC: HLTT) has adopted the model this year to bring healthcare technology forward, including an aggressive acquisitions strategy being spearheaded by newly appointed CEO. This month, Healthtech recruited Edward “Ned” Swanson, M.D. as chief executive officer (https://ibn.fm/KvQt9). Dr. Swanson, who earned his M.D. from Harvard Medical School and was previously a resident in plastic and reconstructive surgery at The Johns Hopkins University School of Medicine, knows success across multiple verticals. Most recently, he co-founded NASDAQ-listed PolarityTE, a biotech company developing a range of regenerative tissue products and biomaterials, led by its flagship product SkinTE(R). PolarityTE also has subsidiaries formed and acquired offering contract research services, adding to Dr. Swanson’s library of scientific, clinical, industry and capital markets knowledge that is exactly what is needed to provide oversight to Healthtech’s portfolio strategy. At Healthtech, Dr. Swanson is leading a family of companies that includes MediScan, the developer of a disruptive technology that converts 2D images from a portable ultrasound into 3D, high-definition images with AI/ML interpretation at the point of care; RevHeart, a company focused on R&D of treatments for heart muscle injury; and VarianBio, a precision oncology company Healthtech recently acquired (https://ibn.fm/bm6KD). VarianBio is developing a proprietary atypical protein kinase C iota (“aPKCi”) inhibitor for the treatment of various tumor types. VarianBio has two pre-clinical assets in development: VAR-101, a topical formulation for basal cell carcinoma (“BCC”), and VAR-102, an oral formulation for an array of solid tumors, including non-small cell lung, pancreatic, and colorectal cancers. VarianBio is looking to penetrate a precision oncology market forecast to grow from $49.9 billion in 2019 to $99.7 billion in 2027. Becoming a subsidiary of Healthtech where it has unfettered access to the experience of the impressive C-suite and board of directors simply makes good sense and will underscore the logic for additional acquisitions. In fact, appeal abounds for all parties in this scenario. For investors, exposure to diverse markets increases upside and mitigates risk with multiple shots on goal. For acquisition targets, there is certainly a financial component with access to the public markets, but that, believe it or not, is not usually the primary motivating factor. The real attraction is leveraging the experience and network of a seasoned management team like Healthtech’s to reach key inflection points. Combining experiences for operational efficiencies and avoidance of pitfalls to meet goals is what drives “good” capital anyway. A parent company like Healthtech isn’t there to micromanage; it is there to assist in making prescient decisions, establish an efficient process and help execute on a business plan. As noted in a recent McKinsey & Company report, the trend towards the biotech portfolio model has been firmly embraced by investors in the past few years. Relatively quiet from 2010-2014, the industry accelerated from 2015-2020, with more than $5.5 billion in capital raised for biotech portfolio companies (https://ibn.fm/4B2ge). Given all the benefits, it wouldn’t be much of a surprise to see investments in the model continue to pile up, providing companies with more capital for more acquisitions. For more information, visit the company’s website at www.HealthTechSolutions.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

• PULL secures edible cannabis gummies order from British Columbia Liquor Distribution Branch
• PULL’s cannabis gummies produced in blister packs using proprietary manufacturing system licensed from US-based Taste-T, LLC
• SKUs include 10 mg THC options in Fire Burst, Strawberry, and Mango flavors, three additional non-THC SKUs currently in development
• Global CBD gummies market estimated at $1.6 billion in 2020, 30.7% CAGR from 2021 to 2028

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, recently secured an initial purchase order through subsidiary Pure Extracts Manufacturing Corp., from the British Columbia Liquor Distribution Branch (“LDB”) for its edible cannabis gummies (https://ibn.fm/xQwPw). Packaged in convenient blister packs, the products use a proprietary manufacturing system licensed from US-based Taste-T, LLC, with 10 mg THC options that include Fire Burst, Strawberry, and Mango flavors. “The edible gummie business is a material revenue producer for Pure Extracts,” said Pure Extracts CEO Ben Nikolaevsky. “We are excited to have received our first purchase order for Fire Burst cinnamon flavored gummies from the wholesaler serving our home province of British Columbia, the LDB, adding them to our provincial distribution and look forward to a successful long-term relationship that leads to a satisfied customer base. With our proprietary manufacturing and packaging machine and our high-quality cannabis extracts, we have created the type of exceptional gummie products that consumers now demand.” Consumer demand for PULL’s Pure Chews branded THC and CBD gummies is strong and continues to grow throughout provincial markets. The Company anticipates that its Fire Burst flavor, like its US counterpart, Taste-T’s, Fireball Cinnamon, will become a best seller across Canada. The global gummies market has experienced staggering growth among consumers wishing to experience the benefits of CBD (https://ibn.fm/itTZJ) without the negative effects of smoking flowers or using vaping devices. Grandview Research valued the global CBD gummies market at $1.6 billion in 2020 and estimates a CAGR of 30.7% from 2021 to 2028 (https://ibn.fm/ucnPy). Pure Extracts expects sales from their initial production run of 50,000 packs to reach $200,000 in revenue from sales in British Columbia, Alberta, Saskatchewan and Ontario, and plans to launch additional non-THC SKUs with varying levels of ultra-high potency CBD in the near future (https://ibn.fm/WQouF). “We plan to replicate the success that our licensing partner, Taste-T, is experiencing in US states including Nevada, Massachusetts, Michigan and Oklahoma,” said Nikolaevsky. “Our exceptionally pure products are in high demand and we have a range in potencies and flavors that consumers will certainly enjoy.” Based in Pemberton, British Columbia, Pure Extracts engages in cannabis toll processing, production of private label THC and CBD-based cannabis products, functional mushroom supplement production and sales, white labeling, and recent developmental activities into the psychedelic mushrooms sector. The Company’s extraction facility is built to European Union GMP standards to secure EU GMP certification for exports to European countries where their products are legal. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• BevCanna expanding distribution of TRACE mineral-rich beverages, supplements into U.S. through new distribution agreement with Benefit Brand Management
• TRACE products feature proprietary plant-based mineral-rich formula sourced from British Columbia’s Rocky Mountains
• Company announced approximated forecasts of $2.4 million revenue, $0.63 million gross profit, based on annual minimum order quantities, committed order queue, and does not include contracts that are yet to be finalized or under negotiation.

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The company recently announced expanded distribution of their TRACE products into the United States through a new agreement with leading wholesaler Benefit Brand Management (https://ibn.fm/JrWT1) along with forecasts of $2.4 million in revenue and $0.63 million in gross based on annual minimum order quantities and its committed white-label beverage order queue (https://ibn.fm/B8Mx2). BevCanna creates, manufactures, and globally distributes iconic beverages that resonate with a health-conscious and well-informed demographic. Sourced from deep within the Rocky Mountains of interior British Columbia, the company’s TRACE line of beverages and nutraceuticals are formulated with a proprietary plant-based formula rich in iron, magnesium, calcium and potassium, designed to appeal to consumers seeking mineral supplementation as a result of mineral deficiencies in the modern food supply. As part of its expansion strategy, the company recently finalized an agreement with leading North American brand and sales management firm Benefit Holdings LLC, dba Benefit Brand Management, to distribute the TRACE line of products in the United States. Starting with health-conscious consumers in New York, Chicago and California, the company has plans to expand its footprint to a growing range of retailers spanning independent specialty retailers to national big-box outlets. “With demand for wellness-focused beverages rapidly increasing among U.S. consumers, this is the ideal time to introduce the TRACE brand to a whole new demographic,” said BevCanna President Melise Panetta. “We’re very excited to work with Benefit on launching the brand, capitalizing on their extensive network and detailed knowledge of the natural products retail landscape in the U.S.” BevCanna also announced forecasts of approximately $2.4 million in revenue and $0.63 million in gross profit for the rolling 12 months starting in July 2021. The company based these figures on annual minimum order quantities for both its Canadian cannabis and Naturo Group white-label beverage operations, including any orders in the company’s queue, less any unfinalized contracts or agreements under negotiation. “We’re thrilled with the progress that we’ve made in securing commitments for both our cannabis-infused and traditional beverage white-label operations,” said Panetta. “There has been strong demand for both operations, and we’re ramping up commercial production for signed clients, with more active customer discussions underway. We’re ready and eager to start production within the month and expect to see products on shelves for the summer season.” Based in British Columbia, BevCanna owns a pristine alkaline spring water aquifer and a world-class HACCP-certified 40,000-square-foot manufacturing facility with an annual 210-million bottling capacity. The company’s extensive retail network spans 3,000+ points of distribution throughout North America. These include its market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with Keef Brands, the #1 cannabis beverage company in the United States. For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• Taking place Saturday, June 26 at Green Karma Farm in Orange, Mass.
• About 40 cannabis industry vendors registered: more spaces still available
• Hosted by The New England Cannabis Convention (NECANN), the largest cannabis and hemp event series in the United States
• Massachusetts is a pioneering adult recreational cannabis use state

When Massachusetts’ voters gave the green light to legalizing adult recreational marijuana use in 2016, the state stood alone among its East Coast neighbors as a place where cannabis cravers could freely pursue their passion. According to the Boston Globe, marijuana sales have since risen to nearly $1.5 billion in total (https://ibn.fm/li6Wx). Massachusetts is no longer unique in its approach to legalizing the leafy green plant, however, and the New England Cannabis Convention (NECANN) has grown to become the largest cannabis and hemp event series in the United States. Its members actively promote legislation favorable to the industry throughout the Northeastern United States, including Massachusetts, particularly on behalf of small cottage industry growers. On Saturday, June 26, NECANN will host its BeanCon event as a one-day gathering for bud buyers and sellers at the Green Karma Farm (210 Wheeler Ave) in Orange, Mass. BeanCon is one in a series of events NECANN has planned to help promote small business operations from Maine to Oklahoma during the coming year. Orange, situated some 70 miles inland from Boston, is bisected by a river and steeped in the New England history. Green Karma Farm is putting a new-old face on the townscape, serving area residents with its mission to provide natural goodness through free-range eggs, CBD products and yoga classes. The home-grown feel of such small businesses provides a bit of pandemic pain relief in the form of greater human connection and a quieter pace of living. The pandemic is reputed to have driven sales of cannabis higher as users look for ways to ease anxiety and physical discomforts that the health emergency’s strictures have brought. BeanCon will be an outdoor event where all attendees and vendors will be required to follow all state COVID safety guidelines regarding in-person capacity limits, protective clothing and interpersonal distancing. BeanCon will nevertheless be a friendly opportunity for cannabis fans to network while browsing the full plant and product displays, shopping at the seed, clone and tissue culture, soil, nutrients and growing aids booths. About 40 vendors are signed up to present at the event, and several booth spaces are still available within the floorplan’s limits. “The show is drawing more quality exhibitors and that leads to better networking. We had a couple of new deals that we struck up that will have a big impact on our business going forward. More out of state customers, investors and engineering are interested in locating in MA and we meet them here,” Gary Arnold of TSRgrow stated. Tickets are $20 and can be obtained through BeanCon’s website, https://necann.com/beancon/